Clinical Trial Update: A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) [Phase 1]

View source ↗

Summary

A Phase 1 study of teprotumumab (TEPEZZA) for diffuse cutaneous systemic sclerosis was terminated, and results were posted on 2024-04-19.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis

Drugs mentioned

• TEPEZZA (teprotumumab)

Snippet

Sponsor: Amgen | Conditions: Diffuse Cutaneous Systemic Sclerosis | Phase 1 | Status: TERMINATED | Results posted: 2024-04-19